Evidence map›Paper›PMID 39503829›Full record

ArticleStem cell reviews and reports2025

Enhancing Late Retinopathy of Prematurity Outcomes with Fresh Bone Marrow Mononuclear Cells and Melatonin Combination Therapy.

Kayvan Mirnia, Masoud Bitaraf, Kosar Namakin, Ashkan Azimzadeh, Saman Behboodi Tanourlouee, Masoume Majidi Zolbin, Ahmad Masoumi, Abdol-Mohammad Kajbafzadeh

Abstract read
PubMed Publisher
In one paragraph

Article in Stem cell reviews and reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kayvan MirniaPediatrics Center of Excellence, Department of Neonatology, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Masoud BitarafPediatric Urology and Regenerative Medicine Research Center, Pediatric Center of Excellence, Gene, Cell & Tissue Research Institute Tehran University of Medical Sciences, Tehran, Iran.
Kosar NamakinPediatric Urology and Regenerative Medicine Research Center, Pediatric Center of Excellence, Gene, Cell & Tissue Research Institute Tehran University of Medical Sciences, Tehran, Iran.
Ashkan AzimzadehPediatric Urology and Regenerative Medicine Research Center, Pediatric Center of Excellence, Gene, Cell & Tissue Research Institute Tehran University of Medical Sciences, Tehran, Iran.
Saman Behboodi TanourloueePediatric Urology and Regenerative Medicine Research Center, Pediatric Center of Excellence, Gene, Cell & Tissue Research Institute Tehran University of Medical Sciences, Tehran, Iran. Behboodisaman09@gmail.com.ORCID 0000-0002-2777-1169
Masoume Majidi ZolbinPediatric Urology and Regenerative Medicine Research Center, Pediatric Center of Excellence, Gene, Cell & Tissue Research Institute Tehran University of Medical Sciences, Tehran, Iran. mmajidizolbin@sina.tums.ac.ir.
Ahmad MasoumiOphthalmology Department and Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Abdol-Mohammad KajbafzadehPediatric Urology and Regenerative Medicine Research Center, Pediatric Center of Excellence, Gene, Cell & Tissue Research Institute Tehran University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRetinopathy of prematurity (ROP) is a vasoproliferative disease affecting premature neonates with life-lasting impacts. This study aims to investigate the long-term functional outcomes and alterations in neural retina architecture following the intravitreal transplantation of bone marrow mononuclear cells (BMMNC) in the rat models of ROP, and to evaluate the effect of adjunctive therapy with melatonin.

methods32 neonate rats were employed. The ROP model was developed in 10 neonatal rats, and two were assigned as control. The ROP models received BMMNC suspension, containing 1.2 × 10

resultsCell therapy alone and with melatonin increased retinal thickness, and improved oscillatory potentials on ERG. Combination therapy increased horizontal and retinal ganglion cell populations. All treatments improved synaptic maturity in the inner plexiform layer, but only combination therapy was effective on the outer plexiform layer.

conclusionMelatonin and BMMNCs combination therapy effectively ameliorates retinal structural and functional deficits at later ROP stages, without causing severe adverse effects. It significantly increases the survival of post-receptor retinal neurons and preserves retinal synaptic structures in the long term, highlighting the promising potential of this novel combination therapy approach to minimize visual deficits in ROP patients.

Indexed as

Bone Marrow CellsBone Marrow TransplantationMelatoninRetinopathy of PrematurityAnimalsAnimals, NewbornCombined Modality TherapyDisease Models, AnimalElectroretinographyRatsRats, Sprague-DawleyRetinaMelatoninCell therapyOxygen induced retinopathyRetinal regenerationRetinal remodelingSynaptic maturationVisual impairment

Identifiers

PMID39503829

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.